

## Lightning Talks I

**6:30-7:30 p.m. | Essex Ballroom**  
**Session Chair: Eliezer Van Allen, DFCI**

1. **Docetaxel and the Tumor Targeting Interleukin-12 (IL-12) PDS01ADC in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)\***  
 Melissa Lauren Abel  
 National Institute of Health, Bethesda, MD
2. **A dependency map of androgen receptor activity identifies drivers of prostate cancer growth\***  
 Arnab Bose  
 Fred Hutchinson Cancer Center, Seattle, WA
3. **High-dimensional spatial profiling identifies distinct and targetable tumor-infiltrating lymphocyte phenotypes in localized prostate cancer\***  
 Precious Cramer  
 Beth Israel Deaconess Medical Center, Boston, MA
4. **Spatial Mapping of Accessible Chromatin Landscapes in Prostate Cancer\***  
 Leigh Ellis  
 Center for Prostate Disease Research, Bethesda, MD
5. **Divergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity\***  
 Sanjana Eyunni  
 University of Michigan, Ann Arbor, MI
6. **Comprehensive spatial profiling of prostate cancer metastasis: Mapping clonal evolution, microenvironment dynamics, and early metastatic markers\***  
 Mengxiao He  
 Science for Life Laboratory, Solna, Sweden
7. **PARP Inhibition Beyond BRCA in Prostate Cancer: The Roles of MMS22L and NDUFAF4\***  
 Li Jia  
 Brigham and Women's Hospital/Harvard Medical School, Boston, MA
8. **Super-enhancer landscape analysis reveals a HOXB13-HNF1A transcriptional axis driving hepatic reprogramming in castration-resistant prostate cancer\***  
 Mingyu Liu  
 University of Massachusetts, Boston, MA
9. **The temporal dynamics of the immune response to neoadjuvant androgen deprivation therapy suggest a window-of-opportunity for checkpoint inhibitor therapy in prostate cancer\***

Kent Nastiuk  
 Roswell Park, Buffalo, NY

10. **Dissecting the role of CHD1 as a key regulator of pro-metastatic transcriptional reprogramming in BRCA2-mutant prostate cancer**  
 Jingzhu Hao  
 University of Massachusetts, Boston, MA
11. **Enhancing androgen receptor antagonist-mediated interferon responses in prostate cancer\***  
 Larysa Poluben  
 Beth Israel Deaconess Medical Center, Boston, MA
12. **Combining CBP/p300 and PARP inhibitors to enhance anti-tumor efficacy in lethal prostate cancer\***  
 Orly I. Richter  
 National Cancer Institute, Bethesda, MD
13. **Targeting of FOXA1 and FOXA2 by small molecules disables the oncogenic output of castration resistant prostate cancer\***  
 Jean-Philippe Paul Theurillat  
 Institute of Oncology Research, Bellinzona, Switzerland
14. **A cancer vaccine for de novo metastatic prostate cancer: learning patients stratification from the UV1 trial\***  
 Alfonso Urbanucci  
 Oslo University Hospital, Oslo, Norway
15. **Polycomb dysregulation shapes chromatin bivalency critical for prostate cancer lineage plasticity\***  
 Varadha Balaji Venkadakrishnan  
 Dana-Farber Cancer Institute, Boston, MA
16. **Development of a fully humanized vascularized "tumor on a chip" model for prostate cancer liver metastasis\***  
 Katherine Vietor  
 University of Wisconsin-Madison, Madison, WI
17. **Circulating tumor DNA methylation captures epigenetic changes in patients induced by the PRC2 inhibitor ORIC-944\***  
 Amber W. Wang  
 ORIC Pharmaceuticals, South San Francisco, CA
18. **A bypass gateway from cholesterol to sex steroid biosynthesis circumnavigates CYP17A1\***  
 Ziqi Zhu  
 University of Miami, FL